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Abstract
Objectives. To assess the 2009 influenza vaccine A/H1N1 on antibody response, side effects and disease
activity in patients with immune-mediated diseases.
Methods. Patients with RA, SpA, vasculitis (VAS) or CTD (n= 149) and healthy individuals (n= 40) received
a single dose of adjuvanted A/H1N1 influenza vaccine. Sera were obtained before vaccination, and 3
weeks, 6 weeks and 6 months thereafter. A/H1N1 antibody titres were measured by haemagglutination
inhibition (HAI) assay. Seroprotection was defined as specific antibody titre51 : 40, seroconversion as
4-fold increase in antibody titre.
Results. Titres increased significantly in patients and controls with a maximum at Week 3, declining to
levels below protection at Month 6 (P< 0.001). Seroprotection was more frequently reached in SpA and
CTD than in RA and VAS (80 and 82% and 57 and 47%, respectively). There was a significantly negative
impact by MTX (P< 0.001), rituximab (P= 0.0031) and abatacept (P= 0.045). Other DMARDs, glucocortic-
oids and TNF blockers did not significantly suppress response (P= 0.06, 0.11 and 0.81, respectively). A
linear decline in response was noted in patients with increasing age (P<0.001). Disease reactivation
possibly related to vaccination was suspected in 8/149 patients. No prolonged side effects or A/H1N1
infections were noted.
Conclusions. The results show that vaccination response is a function of disease type, intensity and
character of medication and age. A single injection of adjuvanted influenza vaccine is sufficient to protect
a high percentage of patients. Therefore, differential vaccination recommendations might in the future
reduce costs and increase vaccination acceptance.
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Introduction
Patients with immune-mediated diseases have been re-
ported to be at increased risk for potentially lethal bacter-
ial and viral infections, especially when treated with
immune-suppressive medication [1, 2]. However, despite
evidence, vaccination rate of this population is low [3, 4].
Traditional arguments against vaccination include reacti-
vation of disease, insufficient response and vaccination
side effects [57].
In 2009, discussion about vaccination was reactivated
by the pandemic swine flu caused by an influenza variant
A/H1N1. This encouraged us to study the immune re-
sponse of immune-compromised patients and medical
staff—both from our department—using a prospectively
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controlled vaccination protocol. As it was assumed that
seasonal influenza and the variant A/H1N1 would not be
covered by a single vaccine (either the seasonal or the
A/H1N1 vaccine), all individuals were asked to get their
annual vaccination against seasonal influenza. We then
decided on a single injection of A/H1N1 vaccine in con-
trols as well as in patients expecting an enhanced immune
response due to the adjuvanted preparation.
Patients and methods
Between 11 November and 17 December 2009, a total of
189 participants were enrolled in the study comprising
149 patients and 40 healthy controls (Table 1). All individ-
uals were seen, all data and sera collected and all vaccin-
ations performed by one person (S.A.). Blood was
collected prior to vaccination (T0), and 3 weeks (T1),
6 weeks (T2) and 6 months (T3) thereafter. Sera were
kept at 20C until analysis. Exclusion criteria were preg-
nancy, allergy to seasonal influenza vaccination or chick-
en eggs and former severe side effects after seasonal
influenza vaccination. Participants received question-
naires regarding side effects (covering the first 5 days
after vaccination and asking for fever, shivering, head-
ache, bone pain, malaise, local pain at the site of injection,
local redness, local swelling, ecchymosis, etc.). Diagnosis
of influenza, hospitalization and/or urgent medical
consultation had to be monitored separately. The study
was approved by the local ethics committee [Kantonale
Ethikkommission Bern (KEK)]. Patients gave written in-
formed consent prior to study participation.
Vaccine
Participants received an i.m. single-shot of adjuvanted
split influenza A/H1N1 vaccine [A/California/7/2009
(H1N1) v-like strain (X-179A) of 3.75 mg, containing AS
03 as adjuvant, Glaxo SmithKline]. Seasonal influenza
vaccination with split inactivated influenza virus containing
15 mg each of the strains A/Brisbane/10/2007 (H3N2),
A/Brisbane/59/2007 (H1N1) and B/Brisbane/60/2008
(Sanofi Pasteur MSD) had been performed in 127/149 pa-
tients and in 28/40 controls at a mean of 4 and 3.7 weeks,
respectively, prior to participation. It was intended to allow
for antibody production against seasonal influenza at first
and to describe an effect of seasonal influenza vaccin-
ation to vaccination against A/H1N1.
Antibody assays
All sera were prepared for determination of antibody re-
sponse at one time point and transferred at one time point
by one person from Bern to Paris (J.W.). All determin-
ations were performed in one effort in the Laboratory of
Virology in Paris by one person (A.K.).
TABLE 1 Overview of patient characteristics
Patient characteristics RA (n= 47) SpA (n= 59) Vasculitis (n= 15) CTD (n= 28) Controls (n= 40)
n (%) n (%) n (%) n (%) n (%)
Age, years
<40 8 (17) 19 (32) 3 (20) 6 (21) 15 (38)
540 to <60 15 (32) 32 (54) 6 (40) 14 (50) 22 (55)
560 24 (51) 8 (14) 6 (40) 8 (29) 3 (8)
Gender
Male 9 (19) 36 (61) 9 (60) 9 (32) 14 (35)
Female 38 (81) 23 (39) 6 (40) 19 (68) 26 (65)
Vaccination against
seasonal influenza
43 (92) 46 (78) 14 (93) 24 (86) 28 (70)
Medication
None 3 (6.4) 4 (6.8) 1 (6.7) 8 (29)
Steroids
<10 mg 17 (36) 5 (8.5) 10 (67) 4 (14)
510 mg 5 (11) 1 (1.7) 1 (6.7) 4 (14)
DMARDs total 36 (77) 25 (42) 12 (80) 20 (71)
SSZ/HCQ 4 3 0 7
MTX 28 21 7 5
Leflunomide 3 1 2 0
AZA 0 0 2 4
CSA 1 0 1 2
Mycophenolate 0 0 0 2
TNF-a 15 (32) 45 (76) 5 (33) 3 (11)
TNF-a+ MTX 10 (21) 16 (27) 4 (27) 3 (11)
Other 21 (45) 6 (10) 4 (27) 5 (18)
Rituximab 5 0 3 0
Abatacept 10 6 0 4
Tocilizumab 5 0 0 0
CYC 1 0 1 1
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Antibody titres against A/H1N1 were tested by a haem-
agglutination inhibition (HAI) test modified from the Center
for Disease Control (CDC) guidelines [8]. Briefly, sera were
treated with receptor-destroying enzyme to remove non-
specific inhibitors. Two-fold dilutions of treated sera, be-
ginning 1 : 10, were tested against four haemagglutinin
units of antigen [15 mg split inactivated influenza vaccine
A/California/7/2009 (H1N1)-like strain (NYMC X-179 A)]
vaccine as antigen for antibody measurement (in contrast
to adjuvanted split influenza A/H1N1 vaccine [A/California/
7/2009 (H1N1)v-like strain (X-179A) of 3.75 mg, containing
AS 03 as adjuvant, Glaxo SmithKline] and 15 mg each of
the strains A/Brisbane/10/2007 (H3N2), A/Brisbane/59/
2007 (H1N1) and B/Brisbane/60/2008 (Sanofi Pasteur
MSD) as regular vaccines as described in the vaccine
section) (Sanofi Pasteur, Lyon, France) on human O Rh
red blood cells. The titre of HAI antibodies was defined as
the highest serum dilution that completely inhibits haem-
agglutination. All sera of an individual patient were ana-
lysed on the same microtitre plate. Sera whose titres were
<10 were assigned a titre of 5 for calculation purposes.
Seroprotection was defined as specific antibody titre
51 : 40 (i.e. HAI), seroconversion as a 4-fold titre increase
and the respective seroconversion rate. For interpretation
of the data, we applied the European guidelines proposed
by the Committee for Human Medicinal Products (CHMP)
that are used for evaluation of influenza vaccines in a
healthy population [9]. To our knowledge there are no
comparable criteria in use when analysing vaccination in
patients with immune-mediated diseases. Following these
guidelines, one of the following criteria has to be fulfilled in
order to assume sufficient protection in healthy subjects
aged 1860 years (>60 years): HAI51 : 40 in at least 70%
(60%) of participants, seroconversion in at least 40%
(30%) of participants and mean increase of the geometric
mean titre (GMT)52.5 (2.0).
Statistical analysis
Data are described with statistical descriptive statistics.
Multivariate regression analysis was performed by the
generalized estimated equations model for titres and sero-
conversion; the multiple logistic regression model was
applied for the seroprotection rate. A P< 0.05 was con-
sidered statistically significant. Confidence intervals were
not calculated as they are not recommended for vaccin-
ation against influenza [10].
Results
Patients vs controls
Baseline seroprotection prior to vaccination measured by
HAI 51 : 40 was low in all groups. Protection rates and
fulfilment of CHMP criteria are summarized in Table 2.
While the three criteria are fulfilled in controls throughout
the study period, seroprotection in patients declined from
70% at T1 to 29% at T3. Individual protection—i.e. pro-
tective values by either HAI or seroconversion—was
reached in 39 (98%) controls and in 113 (75%) patients.
Vaccination response and type of disease
Response rates were better in SpA and CTD than in RA
and vasculitis (VAS) (Table 3). The group of SpA patients
showed immune protection throughout the study period.
CTD patients showed the highest titre increase; however,
none of the required criteria was met at T3. RA patients
showed an unexpected low immune response, possibly in
part explained by age, in part by medication (see below).
VAS patients produced marginally sufficient values until T2.
Influence of medication
The strongest negative effects were seen with abatacept,
rituximab and MTX (P= 0.045, P= 0.031 and P< 0.001).
Patients treated with abatacept or rituximab never
reached sufficient values regarding CHMP criteria. MTX
TABLE 3 Immune response separated for disease groups
Disease T1 T2 T3 T4
CHMP
criteria
RA (n= 47)
HAI 51 : 40, % 17 57 54 30 >70
GMT 9.7 40.8 33.3 20.9
GMT ratio 4.2 3.4 2.2 >2.5
Seroconversion, % 53 43 28 >40
SpA (n= 59)
HAI 51 : 40, % 7 80 66 29 >70
GMT 7.1 61.3 42.0 19.5
GMT ratio 8.6 5.9 2.7 >2.5
Seroconversion, % 75 63 42 >40
VAS (n= 15)
HAI 51 : 40, % 7 47 36 21 >70
GMT 9.5 26.4 24.2 14.9
GMT ratio 2.8 2.6 1.6 >2.5
Seroconversion, % 47 40 20 >40
CTD (n= 28)
HAI 51 : 40, % 7 82 73 30 >70
GMT 9.1 51.6 38.9 20.0
GMT ratio 5.7 4.3 2.2 >2.5
Seroconversion, % 68 61 29 >40
TABLE 2 Immune response in patients and controls
Patients versus
controls T1 T2 T3 T4
CHMP
criteria
Patients (n= 149)
HAI 51 : 40, % 10 68 59 27 >70
GMT 8.5 47.7 36.2 19.6
GMT ratio 5.6 4.3 2.3 >2.5
Seroconversion, % 64 54 33 >40
Controls (n= 40)
HAI 51 : 40, % 10 98 95 75 >70
GMT 8.7 116.0 93.0 51.0
GMT ratio 13.3 10.7 5.9 >2.5
Seroconversion, % 85 80 65 >40
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given subcutaneously at a mean dose of 15.8 mg/week in
61 patients (RA 16 mg, SpA 12.8 mg, VAS 15.4 mg, CTD
19 mg; range 7.530 mg) resulted in 15% lower titres than
in the overall patient group at T1. Despite this reduction,
protection was reached according to the GMT criteria until
T2 (Table 4).
TNF blockers showed the least suppressive effect on
antibody response and a 51% higher increase in titre
compared with MTX-treated patients. The combination
of MTX and TNF blocker inhibited immune response to a
lesser degree than MTX alone (P= 0.07; Table 4).
Patients receiving DMARDs without MTX showed the
second best response rates, resulting in immune protec-
tion throughout the study period (P= 0.06). Tocilizumab
and cyclophosphamide both significantly impaired im-
mune reaction leading to insufficient immune response.
Glucocorticoids (GCs) at a mean dose of 7.4 mg/day did
not significantly impair antibody response even when
separating for doses <10 and 510 mg/day (P= 0.11).
Patients without any immune-mediating medication
(n= 16: RA 3, SpA 4, VAS 1, CTD 8) showed better
responses compared with 133 patients with medication.
Without medication there was a protection until T3,
whereas this was reached only until T2 when taking any
drug (data not shown). The increasing number of
immune-mediating drugs taken had a negative impact
on immune response (one, two or three drugs: P= 0.01;
four drugs: P< 0.001).
Influence of pre-vaccination, gender and age
Pre-vaccination with seasonal influenza vaccine and
gender had no significant effect on antibody response to
A/H1N1 vaccine (P= 0.14 and 0.76, respectively).
In contrast to controls, we found a linear decline in anti-
body response with increasing age in the patient group
(P< 0.001). Patients <60 years of age showed immune
protection throughout the study, in the large group
560 years of age (n= 52) this lasted only until T2. The
age effect was most pronounced in the SpA group with
patients <40 years of age resembling responses in
healthy individuals.
Side effects
Overall, there was no marked difference in side effects
between the patient group and the control group.
Questionnaires were returned by 95 patients (64%) and
26 controls (65%), showing moderate symptoms of shi-
vering (patients/controls, n= 13/3), headache (n= 9/3),
joint pain (n= 9/3) and malaise (n= 7/1). Moderate-
to-severe local pain was noted by 32 (34%) patients and
mild local pain by 11 (42%) controls. There were no re-
ports about rise in body temperature, influenza, hospital-
ization and/or urgent medical consultation.
Course of disease
An increase of disease activity was seen in 32 patients
(15 RA, 12 SpA, 1 VAS, 4 CTD) during the entire study
period. In eight patients, this was noted during the first
2 months after vaccination. The timely correlation might
suggest a causal role of vaccination. Overall mild symp-
toms led to IA GC injections in one RA and one SpA pa-
tient and an increase of oral GCs in another RA patient.
Discussion
After influenza A /H1N1 vaccination, patients, analysed as
one cohort, had a lower antibody response and a shorter
duration of protective antibody levels than controls.
Nevertheless, the CHMP criteria were fulfilled for the
duration of an influenza season. Thus, despite a compro-
mised immune system due to disease and/or immune-
suppressive treatment, vaccination with a single dose of
adjuvanted vaccine is sufficient to induce protection
against influenza in patients with systemic autoimmune
diseases.
The excellent vaccination responses seen in SpA and
CTD patients are remarkable, as is the negative impact of
MTX, abatacept and rituximab and, on the other hand, the
minimal suppressive effect of TNF blockers.
TABLE 4 Immune response separated for medication
Medication T1 T2 T3 T4
CHMP
criteria
MTX (n= 28)
HAI 51 : 40, % 11 50 41 25 >70
GMT 8.7 32.5 26.1 18.6
GMT ratio 3.8 3.0 2.2 >2.5
Seroconversion, % 50 36 29 >40
TNF-a (n= 35)
HAI 51 : 40, % 9 91 78 36 >70
GMT 7.9 83.3 57.8 22.4
GMT ratio 10.5 7.3 2.8 >2.5
Seroconversion, % 83 66 46 >40
MTX + TNF-a (n= 33)
HAI 51 : 40, % 6 63 61 20 >70
GMT 6.9 37.6 28.3 14.3
GMT ratio 5.4 4.1 2.1 >2.5
Seroconversion, % 64 61 27 >40
GCs (n= 50)
HAI 51 : 40, % 10.5 66.5 57 27.5 >70
GMT 10.6 55.2 38.7 21.8
GMT ratio 5.2 3.7 2.1 >2.5
Seroconversion, % 59.5 43.5 26 >40
DMARDs (n= 28)
HAI 51 : 40, % 11 79 76 39 >70
GMT 9.5 73.4 55.4 26.9
GMT ratio 7.7 5.8 2.8 >2.5
Seroconversion, % 75 64 46 >40
Abatacept (n= 20)
HAI 51 : 40, % 15 45 35 20 >70
GMT 9.3 23.8 24.2 15.8
GMT ratio 2.5 2.6 1.7 >2.5
Seroconversion, % 35 30 10 >40
Rituximab (n= 8)
HAI 51 : 40, % 13 25 25 25 >70
GMT 10.0 21.0 22.9 16.2
GMT ratio 2.1 2.3 1.6 >2.5
Seroconversion, % 25 25 13 >40
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The good responses in SpA patients might in part be
due to their younger age (32 patients <40 years of age).
This appears to be supported by the age-dependent
response. However, interpretation is difficult as younger
patients are over-represented in the SpA group and there-
fore influence calculations. Furthermore, age dependency
was not found by other investigators [11]. In conclu-
sion, patients with SpA are sufficiently protected by a
single dose of adjuvanted vaccine, independent of age
and medication.
In the RA group with most patients 560 years of age
(51%) we found the highest numbers of MTX, abatacept
and rituximab used. Thus, age and medication combine
in suppressing vaccination response. Data regarding
medication-mediated effects on vaccination in RA are
controversial. Some data report on lower, but still suffi-
cient responses, without impairment by MTX [12, 13]. On
the other hand, even a positive effect of MTX and a
negative effect of TNF blockers on immune response to
seasonal influenza vaccination were reported [14]. A
likely explanation for the discrepant MTX results is
dose and route of administration: in comparison with
other centres we strictly administer MTX subcutaneously,
and our mean dose of 15.8 mg/week is higher than that
in most published cohorts. In lupus patients, a negative
humoral as well as cell-mediated response to influenza
vaccination is described, in particular during active dis-
ease, and possibly depending on the type of vaccine
used [15]. In our group only, one of nine SLE patients
had post-immunization antibody titres below recom-
mended levels. This patient suffered active lupus neph-
ritis and received cyclophosphamide until 2 months
before vaccination followed by MMF plus low-dose
GCs. A combination of disease activity and immunosup-
pression might have contributed to this negative re-
sponse. The otherwise good response in the CTD
group appears to be due to the higher number of pa-
tients without medication. As shown, medication and
number of immune-mediating drugs negatively influence
vaccination response.
Due to its B-cell-depleting properties, rituximab
gained special attention regarding issues of vaccination.
Several studies have led to the conclusion that vaccin-
ation, in particular vaccination against Pneumococcus
species, should be performed prior to the first infusion
[16, 17]. In our cohort, six of eight patients treated with
rituximab showed insufficient antibody responses.
Surprisingly, the two responders were vaccinated 1
and 3 months, respectively, after rituximab. None of
the patients with insufficient response experienced in-
fection so one might hypothesize that cellular immune
response compensated for the humoral deficit [18]. The
lack of a measurable immunosuppressive effect of GCs
is probably best explained by the low mean dose and
the lack of a dose dependency by the fact that most
patients with low-dose GCs are treated concomitantly
with DMARDs.
A positive effect of pre-vaccination against seasonal in-
fluenza was presumed and reflected in the high
percentage of pre-vaccinated patients (85%) and controls
(62%). Yet, pre-vaccination had no positive influence on
the antibody response to the A/H1N1 vaccine in our study.
This is in line with recent data from a healthy cohort
including elderly subjects [19].
In contrast to a recent study on the influence of synthet-
ic and biologic DMARDs on antibody response to the ad-
juvanted pandemic influenza vaccine, we used a single
injection of vaccine instead of a repeated dose as well
in controls as in patients leading to a sufficient antibody
response in the majority of our patients without a single
A/H1N1 infection [20]. We therefore still do not recom-
mend a generalized second vaccine dose for patients
receiving DMARDs of any kind. Furthermore, we mea-
sured vaccine response over a longer period of time.
This allows for the information that patient’s protection
against pandemic influenza is no longer sufficient at
6 months after vaccination with regard to all three
CHMP criteria. Yearly repetition of vaccination can
hereby be supported.
The main weakness of this study is the heterogeneity
and the small size of certain patient populations, the low
number of controls over 60 years of age and low numbers
of certain drugs. On the other hand, we were able to ana-
lyse the largest cohort of SpA patients published to date.
Furthermore, the high number of patients treated with TNF
blockers and/or MTX allowed robust statistical analysis
and could lead to differential vaccination recommenda-
tions in the future.
The results of this study clearly show that vaccination
response is a function of disease type, intensity and
character of medication and of age. A single injection
of adjuvanted influenza vaccine is sufficient to protect a
high percentage of patients. Thus, recommendations
of health authorities, which are largely based on re-
sults obtained with cohorts of healthy individuals, should
not be extrapolated to patients with immune-mediated
diseases.
Rheumatology key messages
. Pandemic influenza vaccination is effective and safe
in patients with immune-mediated diseases.
. A single-dose adjuvanted A/H1N1 vaccine protects
the majority of patients with immune-mediated
diseases.
. Yearly influenza vaccination is recommended be-
cause of the loss of viral protection 6 months
after vaccination.
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